OVID
Ovid Therapeutics Inc
2.40$
-2.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +30.3% | +4.2% | +14.2% | +2.4% | -56.1% | +71.1% | +4,724.6% | -97.9% | +443.9% | -100.0% | – | – | |
| – | -0.3% | -66.1% | +8.8% | +14.2% | – | – | -65.1% | -82.8% | +158.8% | -20.5% | -54.3% | – | |
| – | +30.3% | +4.2% | +14.2% | +2.4% | -56.1% | +71.1% | +4,724.6% | -97.9% | +443.9% | -104.9% | – | – | |
| – | +99.5% | -2.3% | +21.0% | -37.6% | -24.6% | +12.4% | -2.9% | -9.2% | +12.2% | +69.7% | -10.9% | – | |
| – | -9.1% | +15.8% | +13.1% | -31.6% | +22.2% | -11.1% | -19.0% | +39.0% | -5.4% | +3.8% | -7.4% | – | |
| – | +51.0% | -4.2% | +17.8% | -35.2% | -19.4% | +17.4% | -10.5% | +11.5% | +2.8% | +37.2% | -7.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -264.4% | – | – | – | – | – | -275.8% | – | – | |
| – | -100.9% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -264.4% | – | – | – | – | – | -275.8% | – | – | |
| – | – | – | – | -259.6% | – | – | – | – | – | -284.0% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.